4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

Key Points

• This research aims to determine if a 4% tetrasodium EDTA locking fluid can decrease complications associated with central venous access devices in adult ICU patients.
• Randomized trial comparing 4% tetrasodium EDTA locking fluid with standard care
• Conducted in intensive care units with adult patients
• Evaluated the rates of CVAD complications
• Introduction of 4% tetrasodium EDTA significantly reduced the rate of CVAD complications compared to usual care
• Exact event rates and statistical metrics were not provided, but outcomes favored the tetrasodium EDTA group